Colchicine

Generic Name: Colchicine

Brand Names: Colcrys, Gloperba, Lodoco, Mitigare

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅NO_₆

CAS Number: 64-86-8

Unique Ingredient Identifier: SML2Y3J35T

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.

Indication: Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.

Associated Conditions: Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke

Clinical Trials

The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury

Phase 3

Conditions: Reperfusion Injury, Myocardial

Interventions: Drug: Placebo (lactose)
Drug: Colchicine

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-21

Lead Sponsor: Indonesia University

Target Recruit Count: 80

Registration Number: NCT05734612

Locations: 🇮🇩
Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia

Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis

Phase 3

Not yet recruiting

Conditions: Pericarditis Idiopathic Recurrent

Interventions: Drug: Colchicine
Drug: Hydroxychloroquine

First Posted Date: 2023-02-21

Last Posted Date: 2023-02-22

Lead Sponsor: Hippocration General Hospital

Target Recruit Count: 30

Registration Number: NCT05737680

Locations: 🇬🇷
"Hippokration" General Hospital of Athens, Athens, Attiki, Greece

Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome

Phase 2

Recruiting

Conditions: Coronary Artery Bypass
Postpericardiotomy Syndrome
Acute Coronary Syndrome
Myocardial Reperfusion
Coronary Artery Disease
Perioperative Myocardial Infarction
Postoperative Atrial Fibrilation

Interventions: Drug: Colchicine

First Posted Date: 2023-02-13

Last Posted Date: 2023-02-13

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 100

Registration Number: NCT05726019

Locations: 🇧🇷
Heart Institute - University of São Paulo, São paulo, Sao Paulo, Brazil

Effect of Colchicine on MMP-9, NOX2, and TGF-β1 in Myocardial Infarct

Phase 4

Recruiting

Conditions: ST Elevation Myocardial Infarction
Cardiac Remodeling, Ventricular
Colchicine

Interventions: Drug: Colchicine
Procedure: Percutaneous Coronary Intervention
Other: Optimal medical treatment including statin, aspirin, P2Y12 inhibitor, and nitrate.

First Posted Date: 2023-02-02

Last Posted Date: 2023-04-11

Lead Sponsor: RSD dr. Soebandi

Target Recruit Count: 148

Registration Number: NCT05709509

Locations: 🇮🇩
RSD dr Soebandi, Jember, Jawa Timur, Indonesia

Prednisolone Versus Colchicine for Acute Gout in Primary Care

Phase 4

Recruiting

Conditions: Acute Gout

Interventions: Drug: Colchicine 0.5 mg Oral Tablet
Drug: Prednisolone 30 mg Tablet

First Posted Date: 2023-01-26

Last Posted Date: 2025-04-22

Lead Sponsor: University Medicine Greifswald

Target Recruit Count: 314

Registration Number: NCT05698680

Locations: 🇩🇪
Arztpraxis Burgtorstr. 2, Ittlingen, Baden-Württemberg, Germany
🇩🇪
Hausarztpraxis Neckarsteinacher Str. 22, Neckargemünd, Baden-Württemberg, Germany
🇩🇪
Hausarztpraxis Kleinfeldlein 3, Bad Bocklet, Bayern, Germany

and more 62 locations

Colchicine and Inflammation in Hemodialysis Patients

Phase 2

Recruiting

Conditions: End Stage Renal Disease on Dialysis

Interventions: Drug: Colchicine 0.5 MG
Drug: Placebo

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Assaf-Harofeh Medical Center

Target Recruit Count: 50

Registration Number: NCT05677555

Locations: 🇮🇱
Asaf ha Rofeh, MC, Zrifin, Israel

Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

Completed

Conditions: Post-COVID-19 Syndrome
Lung Fibrosis

Interventions: Drug: Corticosteroids alone
Drug: Corticosteroids + Colchicine + Pirfenidone for ≥ 14 days
Drug: Corticosteroids + Colchicine
Drug: Corticosteroids + Pirfenidone

First Posted Date: 2022-12-13

Last Posted Date: 2022-12-13

Lead Sponsor: Mansoura University

Target Recruit Count: 200

Registration Number: NCT05648734

Locations: 🇪🇬
Mansoura University, Mansoura, Dakahlia, Egypt

Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

Phase 1

Recruiting

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction
Colchicine

Interventions: Drug: Colchicine

First Posted Date: 2022-12-05

Last Posted Date: 2025-04-10

Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Target Recruit Count: 40

Registration Number: NCT05637398

Locations: 🇷🇺
A Shchendrygina, Moscow, Russian Federation
🇷🇺
Anastasia Shchendrygina, Moscow, Russian Federation

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Phase 3

Recruiting

Conditions: Cardiovascular Diseases
Diabete Type 2

Interventions: Drug: Aspirin
Drug: Aspirin Placebo
Drug: Colchicine
Drug: Colchicine Placebo

First Posted Date: 2022-12-01

Last Posted Date: 2024-06-06

Lead Sponsor: Montreal Heart Institute

Target Recruit Count: 10000

Registration Number: NCT05633810

Locations: 🇨🇦
Montreal Heart Institute, Montréal, Quebec, Canada

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

Phase 4

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Colchicine

First Posted Date: 2022-11-16

Last Posted Date: 2025-04-15

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 700

Registration Number: NCT05618353

Locations: 🇺🇸
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States
🇺🇸
VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
🇺🇸
VA NY Harbor Healthcare System, New York, NY, New York, New York, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy